NASDAQ : SPRY
ARS Pharmaceuticals, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 3.66 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 363.98M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 293.37M |
| Enterprise Value | 321.13M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 5, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 99.45M |
| Shares Outstanding | 99.45M |
| Shares Change (YoY) | +1.43% |
| Shares Change (QoQ) | +0.02% |
| Owned by Insiders (%) | 6.15% |
| Owned by Institutions (%) | 57.42% |
| Float | 48.03M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 2.70 |
| Forward PS | 2.21 |
| PB Ratio | 26.86 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 2.94 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 3.48 |
| Quick Ratio | 3.15 |
| Debt / Equity | 13.72 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -28.76 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -210.35% |
| Return on Assets (ROA) | -48.02% |
| Return on Invested Capital (ROIC) | -602.38% |
| Return on Capital Employed (ROCE) | -114.65% |
| Weighted Average Cost of Capital (WACC) | 7.83% |
| Revenue Per Employee | $584,635 |
| Profits Per Employee | -$1.08M |
| Employee Count | 200 |
| Asset Turnover | 0.42 |
| Inventory Turnover | 4.77 |
Taxes
| Measure | Value |
|---|
| Income Tax | -80,000 |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.08 |
| 52-Week Price Change | -66.52% |
| 50-Day Moving Average | 4.52 |
| 200-Day Moving Average | 7.35 |
| Relative Strength Index (RSI) | 24.79 |
| Average Volume (20 Days) | 1,609,958 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 19.82M |
| Short Previous Month | 21.19M |
| Short % of Shares Out | 19.93% |
| Short % of Float | 41.26% |
| Short Ratio (days to cover) | 13.03 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 116.93M |
| Gross Profit | 68.22M |
| Operating Income | -216.27M |
| Pretax Income | -215.51M |
| Net Income | -215.43M |
| EBITDA | -214.65M |
| EBIT | -216.27M |
| Loss Per Share | -$2.18 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 143.85M |
| Total Debt | 171.60M |
| Net Cash | -27.76M |
| Net Cash Per Share | -$0.28 |
| Equity (Book Value) | 12.51M |
| Book Value Per Share | 0.13 |
| Working Capital | 150.65M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -196.41M |
| Capital Expenditures | -197,000 |
| Depreciation & Amortization | 1.62M |
| Net Borrowing | 96.26M |
| Free Cash Flow | -196.60M |
| FCF Per Share | -$1.98 |
Margins
| Measure | Value |
|---|
| Gross Margin | 58.35% |
| Operating Margin | -184.96% |
| Pretax Margin | -184.31% |
| Profit Margin | -184.24% |
| EBITDA Margin | -183.57% |
| EBIT Margin | -184.96% |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -1.43% |
| Shareholder Yield | -1.43% |
| Earnings Yield | -73.75% |
| FCF Yield | -62.17% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $24.33 |
| Price Target Difference | 724.75% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (3Y) | 51.03% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -1.36 |
| Piotroski F-Score | 1 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |